<DOC>
	<DOCNO>NCT00627926</DOCNO>
	<brief_summary>A Phase 3 study evaluate efficacy safety two dose regimen telaprevir combination pegylated interferon alfa 2a ( Peg-IFN-alfa-2a ) ribavirin ( RBV ) .</brief_summary>
	<brief_title>A Phase 3 Study Telaprevir Combination With Pegasys速 Copegus速 Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus ( HCV )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Inclusion Criteria Has receive previous treatment approve investigational drug drug regimen treatment hepatitis C Male female subject , 18 70 year age , inclusive Genotype 1 , chronic hepatitis C detectable Hepatitis C Virus ( HCV ) Ribonucleic Acid ( RNA ) Screening laboratory value , test , physical exam within acceptable range Able willing follow contraception requirement Able read understand , willing sign inform consent form abide study restriction Exclusion Criteria Subject contraindication Pegasys速 Copegus速 therapy Evidence hepatic decompensation cirrhotic subject History organ transplant History , current medical condition could impact safety subject participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Genotype 1</keyword>
</DOC>